While Editas Medicine Inc has overperformed by 3.50%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EDIT rose by 4.21%, with highs and lows ranging from $11.91 to $6.08, whereas the simple moving average jumped by 5.41% in the last 200 days.
On October 24, 2023, Citigroup Upgraded Editas Medicine Inc (NASDAQ: EDIT) to Buy. A report published by JP Morgan on October 18, 2023, Upgraded its rating to ‘Neutral’ for EDIT. Stifel September 29, 2023d the rating to Buy on September 29, 2023, and set its price target from $9 to $17. Raymond James June 12, 2023d its ‘Mkt Perform’ rating to ‘Outperform’ for EDIT, as published in its report on June 12, 2023. Cantor Fitzgerald’s report from February 01, 2023 suggests a price prediction of $15 for EDIT shares, giving the stock a ‘Overweight’ rating. Citigroup also rated the stock as ‘Neutral’.
Analysis of Editas Medicine Inc (EDIT)
Further, the quarter-over-quarter increase in sales is 818.74%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Editas Medicine Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -43.17% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.39, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and EDIT is recording an average volume of 1.94M. On a monthly basis, the volatility of the stock is set at 7.60%, whereas on a weekly basis, it is put at 7.73%, with a loss of -13.01% over the past seven days. Furthermore, long-term investors anticipate a median target price of $15.40, showing growth from the present price of $9.16, which can serve as yet another indication of whether EDIT is worth investing in or should be passed over.
How Do You Analyze Editas Medicine Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.76%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 73.22% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
EDIT shares are owned by institutional investors to the tune of 73.22% at present.
